A5047594858- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Lymphoma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Research Studies
- Histone Deacetylase Inhibitors Research
- Viral Infectious Diseases and Gene Expression in Insects
- Genetic factors in colorectal cancer
- Immune Cell Function and Interaction
- Single-cell and spatial transcriptomics
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Plant tissue culture and regeneration
- Multiple and Secondary Primary Cancers
- Transgenic Plants and Applications
- Telomeres, Telomerase, and Senescence
- Liver Diseases and Immunity
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms
- Phytase and its Applications
- Cancer Research and Treatments
Ho Chi Minh City University of Science
2025
Vietnam National University Ho Chi Minh City
2025
NYU Langone Health
2019-2021
Weill Cornell Medicine
2016-2019
Cornell University
1994-2019
NewYork–Presbyterian Hospital
2018
New York Proton Center
2016-2017
University of Manitoba
2014
National Eye Institute
2000
Kettering University
1994
Background Prostate cancer is radiosensitive. Prostate‐specific membrane antigen (PSMA) selectively overexpressed on advanced, castration‐resistant tumors. Lutetium‐177–labeled anti‐PSMA monoclonal antibody J591 ( 177 Lu‐J591) targets prostate with efficacy and dose‐response/toxicity data when delivered as a single dose. Dose fractionation may allow higher doses to be administered safely. Method Men metastatic refractory or refusing standard treatment options normal neutrophil platelet...
Phytases enhance phosphorus bioavailability in animal feed, but their limited reusability hinders application. To overcome this, Saccharomyces cerevisiae was engineered to display a fusion phytase combining acid and alkaline phytases on its cell surface by using CRISPR/Cas9. The enzyme anchored via the α-agglutinin-GPI system two marker-free strains, BY4743::GAP-mGEB BY4743::GAP-aGEB, employing MFα Aga2p signal peptides, respectively. Both strains exhibited robust activity across broad pH...
Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy decitabine combined with CXCR4 antagonist plerixafor newly diagnosed patients acute evaluate effects on stem cells. Patients were treated monthly cycles 20 mg/m2 days 1-10 escalating doses (320-810 mcg/kg) 1-5. Sixty-nine treated, an overall response rate 43%. Adverse karyotype did not predict (P=0.31). Prior hypomethylating agent treatment strongest...
Immune cells express an incredible variety of proteins; by measuring combinations these, cell types influencing disease can be precisely identified. We developed terraFlow, a platform that defines subsets exhaustively combinatorial protein expression. Using high-parameter checkpoint-focused and function-focused panels, we studied classical Hodgkin's lymphoma (cHL), where systemic T have not been investigated in detail. terraFlow revealed immune perturbations patients, including elevated...
Inherent or acquired drug resistance is a major contributor to epithelial ovarian cancer (EOC) mortality. Novel drugs combinations that produce EOC cell death resensitize resistant cells standard chemotherapy may improve patient treatment. After conducting tolerability studies for the multikinase inhibitors dorsomorphin (DM) and it structural analogue LDN-193189 (LDN), these were tested in mouse intraperitoneal xenograft model of EOC. DM significantly increased survival, whereas LDN showed...
<title>Abstract</title> The CRISPR/Cas9 system facilitates precise genome editing in various organisms. In this study, a single-vector was developed for <italic>Saccharomyces cerevisiae</italic>, employing type II Cas9 enzyme from <italic>Streptococcus pyogenes</italic> and single-guide RNA cassette targeting <italic>CAN1.Y</italic> locus on chromosome V. This is broadly applicable across yeast strains, as it utilizes G418 selection, eliminating the need auxotrophic markers. efficiency of...
To investigate mechanisms of apical sorting in the secretory pathway epithelial cells, we expressed varying amounts 165 amino acid isoform vascular endothelial growth factor (VEGF ) and transforming β1 (TGF-β1) via replication defective adenoviruses. Apical both proteins was efficient at low expression levels but saturated or reversed high levels. High TGF-β1 were effective competing VEGF out pathway; however, did not compete TGF-β1. Tunicamycin inhibition experiments showed that polarity...
Coomassie brilliant blue and Ponceau red have traditionally been used to stain electroblotted proteins, since they are compatible with existing N-terminal internal protein microsequencing as well immunoblotting procedures. With recent improvements in sequencing technology, detection of significantly smaller amounts has become necessary. Metal complexes were evaluated alternatives conventional stains. Electroblotted proteins detected by blocking nonspecific sites polyvinylpyrrolidone-40...
5022 Background: Phase 1 and 2 studies of single dose 177Lu-J591 are published. We hypothesized fractionation may improve safety efficacy. Methods: Patients with progressive mCRPC; no selection for PSMA expression. Initially, 6 cohorts 3-6 pts got doses wks apart (20 mCi/m2, escalating to 45 mCi/m2 x2). Subsequently, enrolled in expansion at the recommended phase (RP2D). Planar imaging was semi-quantitatively scored. Endpoints: PSA changes survival (OS); CTC count (CellSearch) cohorts....
Abstract Introduction: Germline single nucleotide polymorphisms (SNPs) have been investigated in several cancers. Repair of DNA damage is a key cellular process involved the development chemotherapy-resistance. The role germline SNPs repair genes (DRGs) determining resistance to DNA-damaging agents urothelial carcinoma (UC) patients not completely understood. Methods: We examined cohort 53 UC (median age 67, 42 males) enrolled our IRB-approved Precision Medicine program. Patients had...
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II1 Apr 2016MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177LU-J591) FOR MCRPC Jaspreet S. Batra, Beerinder Karir, Kavya Pinto-Chengot, Yuliya Jhanwar, Shankar Vallabhajosula, Paul J. Christos, Gillian Hodes, Linda Lam, Ana Molina, Himisha Beltran, Stanley Goldsmith, David M. Nanus, Neil H. Bander, and Scott T. Tagawa BatraJaspreet Batra More articles by this author , KarirBeerinder Karir...
Abstract Background: Phase I and II single dose 177Lu?J591 studies have been published demonstrating safety efficacy in mCRPC. We reported a study of fractionated-double (2 doses given 2 weeks apart), the ability to administer higher cumulative with dose-response also equal or less toxicity. As single-dose, 70 mCi/m2 results at least 30% declines 47% 41% receiving platelet transfusion. When administered divided doses, 80 25% PSA response transfusion; 90 59% 65% getting transfused....
Abstract The incredible variety of proteins associated with immune responses presents a major challenge in monitoring. When combinations these are measured, cell types that influence disease can be precisely identified. Here, we introduce TerraFlow, novel data analysis tool performs an exhaustive search disease-associated populations from high-parameter flow cytometry experiments. Using newly generated dataset, 24-color checkpoint-focused and 18-color function-focused experiments, apply...
You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II1 Apr 2017MP48-18 GERMLINE DNA REPAIR SINGLE NUCLEOTIDE POLYMORPHISMS IN UROTHELIAL CANCER PATIENTS. Panagiotis Vlachostergios, Bishoy Faltas, Tuo Zhang, Linda Lam, Olivier Elemento, and Mark Rubin VlachostergiosPanagiotis Vlachostergios More articles by this author , FaltasBishoy Faltas ZhangTuo Zhang LamLinda Lam ElementoOlivier Elemento RubinMark View All Author...
Radioimmunotherapy is often limited by radiation toxicity due to the long-circulating radiolabeledand body. Pretargeted radoimmunotherapy used mine imize this separating long-citrculating antibody and rapidly cleared radionuclide. Although results from animal studies clinical trials are promising, they have also raised many questions. Preclinical experiences will foster an in-depth understanding of pretargeted radioimmunotherapy as alternative, choice for cancer treatment. Breakthroughs in...